Blockage of CD59 function restores activities of neutralizing and nonneutralizing antibodies in triggering antibody-dependent complement-mediated lysis of HIV-1 virions and provirus-activated latently infected cells

Journal of Virology

Volumn 89, Issue 18, 2015, Pages 9393-9406

  Yang, Kai ^a,b   Lan, Jie ^b   Shepherd, Nicole ^b   Hu, Ningjie ^b   Xing, Yanyan ^b   Byrd, Daniel ^b   Amet, Tohti ^b   Jewell, Corlin ^b   Gupta, Samir ^b   Kounga, Carole ^b   Gao, Jimin ^a   Yu, Qigui ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2.2C; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY A32; MONOCLONAL ANTIBODY N12-I15; MONOCLONAL ANTIBODY N5-I5; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; CD59 PROTEIN, HUMAN; COMPLEMENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY DEPENDENT COMPLEMENT MEDIATED LYSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNITY; LYSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRION; VIRUS ISOLATION; VIRUS STRAIN; WESTERN BLOTTING; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PHYSIOLOGY; PROVIRUS; VIRUS LATENCY;

ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD59; COMPLEMENT SYSTEM PROTEINS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROVIRUSES; VIRION; VIRUS LATENCY;

EID: 84940476397     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01614-15     Document Type: Article

References (89)

1. Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M. 1994. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 93:2505-2513. http://dx .doi.org/10.1172/JCI117260.
2. Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O, Lu XS, Pillot J. 1995. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172:691-697. http://dx .doi.org/10.1093/infdis/172.3.691.
3. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD, Moore JP. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 71:2799-2809.
4. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, Ragnaud JM, Bernard N, Fleury HJ. 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J AIDS Hum Retrovirol 11:438-447. http://dx.doi.org/10.1097/00042560-199604150 -00003.
5. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144-4149. http://dx.doi.org/10.1073 /pnas.0630530100.
6. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A. 2004. Development of the antibody response in acute HIV-1 infection. AIDS 18:371-381. http://dx.doi.org/10 .1097/00002030-200402200-00002.
7. Humbert M, Dietrich U. 2006. The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51-59.
8. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 183: 2708-2717. http://dx.doi.org/10.4049/jimmunol.0901068.
9. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15:866-870. http://dx.doi.org/10.1038/nm .1949.
10. Huber M, Trkola A. 2007. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 262:5-25. http://dx.doi.org/10.1111/j.1365 -2796.2007.01819.x.
11. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
12. Yu Q, Yu R, Qin X. 2010. The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 7:334-340. http://dx.doi.org/10.1038 /cmi.2010.8.
13. McLinden R, Paris R, Polonis V, Close N, Su Z, Shikuma C, Margolis D, Kim J. 2012. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS 26:1452. http://dx.doi.org/10.1097/QAD.0b013e3283550b8e.
14. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, Hraber P, Fischer W, Li H, Wang S, Sterrett S, Keele BF, Ganusov VV, Perelson AS, Korber BT, Georgiev I, McLellan JS, Pavlicek JW, Gao F, Haynes BF, Hahn BH, Kwong PD, Shaw GM. 2012. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 8:e1002721. http://dx .doi.org/10.1371/journal.ppat.1002721.
15. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224-228. http://dx.doi.org/10.1038 /nature12744.
16. Morris L. 2002. Neutralizing antibody responses to HIV-1 infection. IUBMB Life 53:197-199. http://dx.doi.org/10.1080/15216540212656.
17. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF, III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. http://dx.doi.org /10.1126/science.7973652.
18. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905. http://dx.doi.org/10.1128/JVI.75.22 .10892-10905.2001.
19. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17:1757-1765. http://dx.doi.org /10.1089/08892220152741450.
20. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
21. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederost B, Weber R, Stiegler G, Katinger H, Gunthard HF, Trkola A. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 81:8793-8808. http://dx.doi.org/10.1128/JVI.00598-07.
22. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusionassociated motif in gp41. Immunity 22:163-173. http://dx.doi.org/10 .1016/j.immuni.2004.12.011.
23. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard HF. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11:615-622. http://dx.doi.org/10.1038 /nm1244.
24. Hangartner L, Zellweger RM, Giobbi M, Weber J, Eschli B, McCoy KD, Harris N, Recher M, Zinkernagel RM, Hengartner H. 2006. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 203:2033- 2042. http://dx.doi.org/10.1084/jem.20051557.
25. Ward R. 2009. Mechanisms of protection against rotavirus infection and disease. Pediatr Infect Dis J 28:S57-S59. http://dx.doi.org/10.1097/INF .0b013e3181967c16.
26. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP, Hughes M, Jebbett J. 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137-142.
27. Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P. 1989. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol 70(Pt 11):2953-2961.
28. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 2014. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-169. http://dx.doi.org/10.1097 /QAD.0000000000000106.
29. Shin BG, Yun MR, Kim SS, Kim GJ. 2011. Neutralizing antibody responses and evolution of the viral envelope in the course of HIV-1 Korean clade B infection. Osong Public Health Res Perspect 2:151-157. http://dx .doi.org/10.1016/j.phrp.2011.11.038.
30. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. 1997. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78(Pt 8):1907-1911.
31. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. 1996. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) J Exp Med 183:307-310.
32. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT. 1995. Role of virionassociated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182:501-509. http://dx.doi.org/10.1084/jem.182.2.501.
33. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X. 2010. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 184:359-368. http://dx.doi.org/10 .4049/jimmunol.0902278.
34. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H. 1995. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 96:1520-1526. http://dx.doi.org/10.1172/JCI118190.
35. Lan J, Yang K, Byrd D, Hu N, Amet T, Shepherd N, Desai M, Gao J, Gupta S, Sun Y, Yu Q. 2014. Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV- 1-infected cells. J Immunol 193:3577-3589. http://dx.doi.org/10.4049 /jimmunol.1303030.
36. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, Katinger H. 1994. Generation of human monoclonal antibodies against HIV-1 proteins: electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10:359- 369. http://dx.doi.org/10.1089/aid.1994.10.359.
37. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009-4018.
38. Etemad-Moghadam B, Sun Y, Nicholson EK, Karlsson GB, Schenten D, Sodroski J. 1999. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol 73:8873-8879.
39. Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, Bilska M, Zhou JT, Pauza CD, Parren PW, Burton DR, Sodroski JG, Letvin NL, Montefiori DC. 1999. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol 73:10199- 10207.
40. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, Dopper S, Gruber G, Buchacher A, Muster T, Katinger H. 1996. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10:587-593. http://dx.doi.org/10.1097/00002030 -199606000-00003.
41. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, Katinger H. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10:1651-1658. http://dx.doi.org/10.1089/aid.1994.10.1651.
42. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120- CD4 binding. J Virol 67:3978-3988.
43. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. 2002. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retroviruses 18:1207-1217. http://dx.doi.org/10 .1089/08892220260387959.
44. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK. 2013. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 110:E69-E78. http://dx .doi.org/10.1073/pnas.1217609110.
45. Moore JP, Thali M, Jameson BA, Vignaux F, Lewis GK, Poon SW, Charles M, Fung MS, Sun B, Durda PJ, Akerblom L, Wahren B, Ho DD, Sattentau QJ, Sodroski J. 1993. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 67:4785-4796.
46. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69:5723-5733.
47. + T cells is directly associated with the magnitude of surface IgG binding. J Virol 86:8672-8680. http://dx.doi.org/10.1128/JVI.00287-12.
48. Silbermann B, Tod M, Desaint C, Pialoux G, Petitprez K, Slama L, Poncelet H, Moreau C, Mazarin V, Heshmati F, Salmon-Ceron D, Guillet JG, Launay O. 2008. Short communication: long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retroviruses 24:1445-1448. http://dx.doi.org/10.1089/aid.2008 .0107.
49. Byrd D, Amet T, Hu N, Lan J, Hu S, Yu Q. 2013. Primary human leukocyte subsets differentially express vaccinia virus receptors enriched in lipid rafts. J Virol 87:9301-9312. http://dx.doi.org/10.1128 /JVI.01545-13.
50. Ono A. 2010. Relationships between plasma membrane microdomains and HIV-1 assembly. Biol Cell 102:335-350. http://dx.doi.org/10.1042 /BC20090165.
51. Muranyi W, Malkusch S, Muller B, Heilemann M, Krausslich HG. 2013. Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail. PLoS Pathog 9:e1003198. http://dx.doi.org/10.1371/journal .ppat.1003198.
52. Malkusch S, Muranyi W, Muller B, Krausslich HG, Heilemann M. 2013. Single-molecule coordinate-based analysis of the morphology of HIV-1 assembly sites with near-molecular spatial resolution. Histochem Cell Biol 139:173-179. http://dx.doi.org/10.1007/s00418-012-1014-4.
53. Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL. 2014. Antigenic properties of the HIV envelope on virions in solution. J Virol 88:1795-1808. http://dx.doi.org/10.1128/JVI.03048-13.
54. Buratti E, McLain L, Tisminetzky S, Cleveland SM, Dimmock NJ, Baralle FE. 1998. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 79(Pt 11):2709-2716.
55. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
56. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti- human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232-13252. http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
57. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, Katinger H. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68:4031-4034.
58. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fatkenheuer G, Schlesinger SJ, Nussenzweig MC. 2015. Viremia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522:487-491. http://dx.doi.org/10.1038/nature14411.
59. Forthal DN, Landucci G, Daar ES. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75:6953-6961. http://dx.doi.org/10.1128/JVI.75.15.6953-6961.2001.
60. + lymphocyte count. AIDS ResHumRetroviruses 17:553-561. http://dx.doi .org/10.1089/08892220151126661.
61. Nakane T, Nomura T, Shi S, Nakamura M, Naruse TK, Kimura A, Matano T, Yamamoto H. 2013. Limited impact of passive nonneutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. PLoS One 8:e73453. http://dx.doi.org/10 .1371/journal.pone.0073453.
62. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108:11181-11186. http://dx.doi .org/10.1073/pnas.1103012108.
63. Zhu P, Liu J, Bess J, Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. http://dx.doi.org/10 .1038/nature04817.
64. Dong XN, Chen YH. 2006. Neutralizing epitopes in the membraneproximal region of HIV-1 gp41: genetic variability and co-variation. Immunol Lett 106:180-186. http://dx.doi.org/10.1016/j.imlet.2006.06.002.
65. Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK. 2012. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol 86:2930-2941. http://dx.doi.org/10.1128 /JVI.06349-11.
66. Sattentau QJ. 1995. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 9:1383-1385. http://dx.doi.org/10.1097 /00002030-199512000-00017.
67. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F. 2006. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20:1923-1930. http://dx.doi.org/10 .1097/01.aids.0000247113.43714.5e.
68. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 1:a007278. http://dx.doi.org/10.1101/cshperspect.a007278.
69. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13:693-701. http://dx.doi.org/10.1038/nri3516.
70. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433.
71. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activ-ity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85:7029-7036. http://dx.doi.org/10.1128/JVI.00171-11.
72. Matsuo S, Ichida S, Takizawa H, Okada N, Baranyi L, Iguchi A, Morgan BP, Okada H. 1994. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med 180: 1619-1627. http://dx.doi.org/10.1084/jem.180.5.1619.
73. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. 2001. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98:442-449. http://dx.doi.org /10.1182/blood.V98.2.442.
74. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F. 2007. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67:10556-10563. http://dx.doi.org/10.1158 /0008-5472.CAN-07-1811.
75. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socie G, International PNHIG. 2005. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106:3699-3709. http://dx.doi.org/10 .1182/blood-2005-04-1717.
76. Hall C, Richards S, Hillmen P. 2003. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102:3587-3591. http://dx.doi.org/10.1182/blood-2003-01-0009.
77. Richards SJ, Hill A, Hillmen P. 2007. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom 72:291-298.
78. Azenishi Y, Ueda E, Machii T, Nishimura J, Hirota T, Shibano M, Nakao S, Kinoshita T, Mizoguchi H, Kitani T. 1999. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia. Br J Haematol 104:523-529. http://dx.doi.org/10.1046/j.1365 -2141.1999.01214.x.
79. Brodsky RA. 2006. New insights into paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program 24-28:516.
80. Brodsky RA, Hu R. 2006. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leukemia Lymphoma 47: 1215-1221. http://dx.doi.org/10.1080/10428190600555520.
81. Trail PA, King HD, Dubowchik GM. 2003. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52:328-337.
82. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. 2010. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologicae 95:135-143. http://dx.doi.org/10.3324/haematol .2008.001628.
83. + T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8:2. http://dx.doi.org/10.1186/1471 -2334-8-2.
84. Shen L, Siliciano RF. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122:22-28. http://dx.doi.org/10.1016/j.jaci.2008 .05.033.
85. Dahl V, Palmer S. 2009. Establishment of drug-resistant HIV-1 in latent reservoirs. J Infect Dis 199:1258-1260. http://dx.doi.org/10.1086/597760.
86. Pace MJ, Agosto L, Graf EH, O'Doherty U. 2011. HIV reservoirs and latency models. Virology 411:344-354. http://dx.doi.org/10.1016/j.virol .2010.12.041.
87. Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. 2011. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc 14:4. http://dx.doi .org/10.1186/1758-2652-14-4.
88. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142:431-438.
89. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365-2368. http://dx.doi.org/10.1073/pnas.86.7.2365.